300 related articles for article (PubMed ID: 29274334)
1. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
Mesbahi Y; Zekri A; Ahmadian S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Eur J Pharmacol; 2018 Feb; 820():274-285. PubMed ID: 29274334
[TBL] [Abstract][Full Text] [Related]
2. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
Yoshimura Y; Shiino A; Muraki K; Fukami T; Yamada S; Satow T; Fukuda M; Saiki M; Hojo M; Miyamoto S; Onishi N; Saya H; Inubushi T; Nozaki K; Tanigaki K
PLoS One; 2015; 10(6):e0128288. PubMed ID: 26038891
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
6. PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Luo Q; Li Y; Deng J; Zhang Z
Chem Biol Interact; 2015 Jan; 226():12-22. PubMed ID: 25499136
[TBL] [Abstract][Full Text] [Related]
7. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Kryeziu K; Jungwirth U; Hoda MA; Ferk F; Knasmüller S; Karnthaler-Benbakka C; Kowol CR; Berger W; Heffeter P
Mol Cancer Ther; 2013 Jun; 12(6):1073-84. PubMed ID: 23548265
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting of aberrant glucose metabolism in glioblastoma.
Shen H; Decollogne S; Dilda PJ; Hau E; Chung SA; Luk PP; Hogg PJ; McDonald KL
J Exp Clin Cancer Res; 2015 Feb; 34(1):14. PubMed ID: 25652202
[TBL] [Abstract][Full Text] [Related]
10. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
11. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
14. The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.
Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Tumour Biol; 2014 May; 35(5):4567-80. PubMed ID: 24399651
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH.
Han YH; Kim SZ; Kim SH; Park WH
Cancer Lett; 2008 Oct; 270(1):40-55. PubMed ID: 18539383
[TBL] [Abstract][Full Text] [Related]
16. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
17. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
18. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
19. Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest.
Hassani S; Ghaffari SH; Zaker F; Mirzaee R; Mardani H; Bashash D; Zekri A; Yousefi M; Zaghal A; Alimoghaddam K; Ghavamzadeh A
Ann Hematol; 2013 Sep; 92(9):1207-20. PubMed ID: 23645216
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine.
Han YH; Kim SZ; Kim SH; Park WH
Mol Cells; 2008 Aug; 26(2):158-64. PubMed ID: 18596414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
